Related Experiment Video
Updated: May 14, 2026

Frailty Assessment in an Aging Mouse Model
Published on: September 23, 2025
Design and Rationale of the FICAPP Study: Frailty in Cardiac Amyloidosis: Profiling the Phenotype
Elyn Montgomery1, Natasha Gorrie2, Georgia McCaughan3
1St Vincent's Hospital, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; University of Technology Sydney, Sydney, NSW, Australia.
Frailty is common in cardiac amyloidosis, impacting quality of life and disease severity. This study characterizes frailty in these patients to guide future research and interventions.
Area of Science:
- Cardiology
- Geriatrics
- Internal Medicine
Background:
- Cardiac amyloidosis is a serious infiltrative cardiomyopathy with high mortality.
- Frailty, a syndrome of reduced physiological reserve, is poorly understood in cardiac amyloidosis.
- Understanding frailty is crucial for managing patients with this condition.
Purpose of the Study:
- To determine the prevalence and characteristics of frailty in adults with cardiac amyloidosis.
- To investigate the association between frailty and functional status, quality of life, and disease severity.
- To provide a clinical characterization of frailty in cardiac amyloidosis.
Main Methods:
- Prospective, observational, single-centre cohort study.
- Standardized frailty assessment including physical and cognitive frailty.
- Disease characterization and 12-month follow-up of functional status, quality of life, and biomarkers.
Main Results:
- Anticipates a high prevalence of frailty in cardiac amyloidosis patients.
- Expects greater frailty burden to correlate with worse functional status and quality of life.
- Predicts an association between frailty and multisystem disease and advanced disease severity.
Conclusions:
- This study will offer a pragmatic characterization of frailty in cardiac amyloidosis.
- Findings will support hypothesis generation for future longitudinal and interventional studies.
- Aims to improve clinical management and outcomes for patients with cardiac amyloidosis.
More Related Videos
05:53Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
10:04Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
Published on: October 20, 2017
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification